Investors

Investor Relations

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as a novel oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. 

NASDAQ: SCYX
$ 3.62 +0.13 (3.73%)
Day High: 3.69
Day Low:  3.46
Volume:    1,290,594
4:00 PM ET on
Feb 17, 2017

Delayed ~20 min., by eSignal.